At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
In Brief
A Phase 1 clinical trial evaluating Capecitabine and Bevacizumab for Glioblastoma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study involves participants with recurrent glioblastoma brain tumors (GBM). This means that a participant's brain tumor has either returned after being treated by a previous therapy, or has continued to progress despite being treated. The purpose of this study is to provide proof of concept that suppression of MDSCs (myeloid-derived suppressor cells) is feasible in patients with GBM. Rather than targeting tumor cells or immune checkpoints, which has been the focus of recent therapeutic efforts, direct targeting of MDSCs with low dose capecitabine has the potential to reverse the immunosuppressed microenvironment of GBM and thereby reduce tumors
Study Details
Timeline
Interventions
Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.